| 27102208 | The cells exhibited a senescent secretory effector phenotype: KLRG-1+/CD57+/CD160+/CD28- |
| 26711627 | METHODS: Changes in CD8+ T-cell subsets, based on the expression of CD28 and CD57, were analysed in patients with various forms of cancer affecting the lungs, undergoing chemotherapy and in a control group over six months, using multi-colour flow cytometry |
| 26277688 | Aging-associated subpopulations of human CD8+ T-lymphocytes identified by their CD28 and CD57 phenotypes |
| 26277688 | METHODS: We identified, by flow cytometry, subpopulations of CD8+ T-cells based on CD57 and CD28 expression, and tested them for some markers of cellular senescence, apoptosis, differentiation and homing |
| 26097880 | Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cells |
| 26097880 | Upon coincubation with GBM-SCs, we observed strong upregulation of the T cell aging marker CD57, but other phenotypical or functional changes usually associated with terminal T cell differentiation could not immediately be detected |
| 26097880 | Here, we provide evidence suggesting that CD57 is rapidly and efficiently transferred from CD57+ GBM-SCs to preactivated T cells and that the transfer is greatly enhanced by specific CAR/ligand interaction |
| 26097880 | After separation from CD57+ tumor cells, CD57 epitope expression on T cells decreased only slowly over several days |
| 26097880 | We conclude that CD57 transfer from tumor cells to T cells may occur in patients with CD57+ tumors and that it may have to be considered in the interpretation of phenotyping results for tumor-infiltrating lymphocytes and perhaps also in the characterization of tumor-specific T cells from tumor or lymph node homogenates or peripheral blood mononuclear cells |
| 25604328 | Immunosenescence was investigated by analysing CD57(+) CD28(-) levels, immune activation by analysing CD38(+) HLA-DR(+) levels, inflammation by analysing interleukin (IL)-6 levels, and microbial translocation by analysing lipopolysaccharide (LPS) and soluble CD14 (sCD14) levels |
| 25574956 | RESULTS: Activated CD25(+) T cells and activated/senescent CD69(+)/CD57(+)/CD28(null) CD4(+) T cells, interleukin-6, and CRP were associated with PFT abnormalities |
| 25426558 | Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57 |
| 25426558 | Direct contact with patient-derived GBM-SCs caused rapid upregulation of CD57 on the CAR T cells, a molecule known to mark terminally or near-terminally differentiated T cells |
| 25426558 | CD57 is also expressed on tumor cells of neural crest origin and has been preferentially found on highly aggressive, undifferentiated, multipotent CSC-like cells |
| 25426558 | We found that CD57 was upregulated on activated T cells only upon contact with CD57+ patient-derived GBM-SCs, but not with conventional CD57-negative glioma lines |
| 25426558 | However, CD57 was not downregulated on the GBM-SCs upon their differentiation, indicating that this molecule is not a bona fide CSC marker for GBM |
| 25426558 | Differentiated GBM cells still induced CD57 on CAR T cells and other activated T cells |
| 25426558 | Therefore, CD57 can apparently be upregulated on activated human T cells by mere contact with CD57+ target cells |
| 25001861 | The classical markers of alpha/beta T cell aging, including CD28, CD27, and CD57, did not prove significant for gamma/delta T cells |
| 24499954 | Changes were related to proportions of CD4 T cells expressing HLA-DR or CD57 and plasma levels of sCD14, CXCL9 and CXCL10 |
| 24499954 | CD127 expression correlated inversely with proportions of CD4CD57 T cells, and pSTAT5 induction correlated inversely with CD4 T-cell expression of HLA-DR and CD57 |
| 23962178 | Moreover, increased T cell differentiation was observed with higher percentages of CD57+ and CD28null CD4+ and CD8+ memory T cells |
| 23435301 | RESULTS: There was increased frequency of CD4+ and CD8+ T cells with an immunosenescence phenotype (CD57+ and CD28-) in cases vs |
| 22102004 | CD28-, CD57+ and KLRG1+ are cell surface markers that have been used to describe senescent T-lymphocytes in humans |
| 22102004 | Using five-colour flow cytometry, we analyzed peripheral blood T-lymphocytes for their expression of CD28, CD57 and KLRG1 in 11 young (Y) and 11 old (O) apparently healthy human subjects |
| 22102004 | Populations that were more frequent in the elderly participants were characterised as CD28+ CD57+, CD28- CD57+ or CD28- CD57- |
| 20100671 | CD57 expression by T cells in the female genital tract of HIV-zx1 infected women |
| 20100671 | CD57 expression by T cells has been associated with enhanced migratory potential and CD57+ T cells have been shown to accumulate in tissues during the late stages of HIV disease |
| 20100671 | We investigated the impact of HIV-infection and clinical status on the expression of CD57 by T cells from the female genital tract in 13 HIV-infected and 5 uninfected women |
| 20100671 | We found that cervical and blood-derived T cells expressed similar frequencies of CD57 |
| 20100671 | The frequency of CD57 expression by cervical or blood T cells was not associated with clinical status (CD4 counts) |
| 19602548 | As early as 2 months after HSCT, CD8(+) T cells from patients were predominantly CD28(-) CD57(+) and had relatively short telomeres, consistent with cellular senescence |
| 17416406 | CD57 expression correlates with alveolitis severity in subjects with beryllium-induced disease |
| 17416406 | OBJECTIVE: The aims of this study were to determine the relationship between CD57 expression, a marker of T-cell senescence, and severity of chronic beryllium disease (CBD) and to determine the phenotypic and functional characteristics that differentiate beryllium-specific CD4(+) T cells in lung and blood |
| 17416406 | METHODS: CD57 expression on beryllium-responsive IFN-gamma-expressing and IL-2-expressing CD4(+) T cells in blood and lung of 17 beryllium-sensitized and 20 CBD subjects was determined |
| 17416406 | Although CD57 expression on blood and BAL cells was associated with a reduced proliferative potential, examination of beryllium-specific CD4(+) T cells in blood and lung revealed no difference in CD57 expression on cells that produced IFN-gamma only versus IFN-gamma and IL-2 |
| 17416406 | CONCLUSION: These data suggest that CD57 expression on CD4(+) T cells is an important phenotypic marker to assess lung inflammation and the functional competence of the CD4(+) T-cell compartment in CBD |
| 17416406 | CLINICAL IMPLICATIONS: These findings suggest that CD57 is a marker of lung inflammation and potentially, disease severity |
| 17379755 | As a consequence of clonal expansion, some T lymphocytes acquire a senescent phenotype, fail to replicate in response to further antigenic stimulation, and express the killer cell lectin-like receptor G1 (KLRG1) and/or CD57 |
| 17379755 | Blood lymphocytes isolated before, immediately after, and 1 h after exercise were assessed for cell surface expression of KLRG1, CD57, CD28, CD45RA, CD45RO, CD62L, and lymphocyte subset markers (CD3, CD4, CD8, CD56) by flow cytometry |
| 17379755 | The percentage of all CD3+ T lymphocytes expressing KLRG1 and CD57 increased with exercise (P < 0 |
| 17379755 | Mobilized T-lymphocyte populations expressing KLRG1 and CD57 appeared to extravasate the peripheral blood compartment after 1 h of recovery |
